Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway

Neurobiology of Disease

Volumn 62, Issue , 2014, Pages 250-259

  Riverol, Mario ^a,b   Ordóñez, Cristina ^b   Collantes, María ^a,b   DiCaudo, Carla ^b   Peñuelas, Iván ^a,b   Arbizu, Javier ^a   Marcilla, Irene ^b   Luquin, María R ^a,b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Dopaminergic marker; Levodopa; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 6 FLUORODOPA F 18; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE TRANSPORTER; LEVODOPA; PLACEBO; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR PUTAMEN; ARTICLE; CAUDATE NUCLEUS; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DYSKINESIA; ENZYME ACTIVITY; FUNCTIONAL NEUROIMAGING; HAPLORHINI; HISTOLOGY; MACACA FASCICULARIS; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; POSTERIOR PUTAMEN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN CONTENT; PUTAMEN; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA PARS COMPACTA;

(18)F-DOPA POSITRON EMISSION TOMOGRAPHY; DOPAMINERGIC MARKER; LEVODOPA; MPTP; PARKINSON'S DISEASE;

ANIMALS; ANTIPARKINSON AGENTS; AROMATIC-L-AMINO-ACID DECARBOXYLASES; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; LEVODOPA; MACACA FASCICULARIS; MAGNETIC RESONANCE IMAGING; MALE; NEURAL PATHWAYS; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; SUBSTANTIA NIGRA;

EID: 84887013222     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.09.014     Document Type: Article

References (49)

1. Betarbet R., Turner R., Chockkan V., DeLong M.R., Allers K.A., Walters J., Levey A.I., Greenamyre J.T. Dopaminergic neurons intrinsic to the primate striatum. J. Neurosci. 1997, 17:6761-6768.
2. Blesa J., Juri C., Collantes M., Peñuelas I., Prieto E., Iglesias E., Martí-Climent J., Arbizu J., Zubieta J.L., Rodríguez-Oroz M.C., García-García D., Richter J.A., Cavada C., Obeso J.A. Progression of dopaminergic depletion in a model of MPTP-induced parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study. Neurobiol. Dis. 2010, 38:456-463.
3. Blesa J., Pifl C., Sánchez-González M.A., Juri C., García-Cabezas M.A., Adánez R., Iglesias E., Collantes M., Peñuelas I., Sánchez-Hernández J.J., Rodríguez-Oroz M.C., Avendaño C., Hornykiewicz O., Cavada C., Obeso J.A. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study. Neurobiol. Dis. 2012, 48:79-91.
4. Blunt S.B., Jenner P., Marsden C.D. Suppressive effect of l-DOPA on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov. Disord. 1993, 8:129-133.
5. Bruck A., Aalto S., Nurmi E., Vahlberg T., Bergman J., Rinne J.O. Striatal subregional 6-[18F]fluoro-l-DOPA uptake in early Parkinson's disease: a two year follow-up study. Mov. Disord. 2006, 21:958-963.
6. Cho S., Neff N.H., Hadjiconstantinou M. Regulation of tyrosine hydroxylase and aromatic l-amino acid decarboxylase by dopaminergic drugs. Eur. J. Pharmacol. 1997, 323:149-157.
7. Cho S., Duchemin A.M., Neff N.H., Hadjiconstantinou M. Tyrosine hydroxylase, aromatic l-amino acid decarboxylase and dopamine metabolism after chronic treatment with dopaminergic drugs. Brain Res. 1999, 830:237-245.
8. Collantes M., Prieto E., Peñuelas I., Blesa J., Juri C., Martí-Climent J.M., Quincoces G., Arbizu J., Riverol M., Zubieta J.L., Rodriguez-Oroz M.C., Luquin M.R., Richter J.A., Obeso J.A. New MRI, 18F-DOPA and 11C-(+)-alpha-dihydrotetrabenazine templates for Macaca fascicularis neuroimaging: advantages to improve PET quantification. Neuroimage 2009, 47:533-539.
9. Datla K.P., Blunt S.B., Dexter D.T. Chronic l-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov. Disord. 2001, 16:424-434.
10. Di Caudo C.G., Riverol M., Carril-Mundiñano I., Ordoñez-Camblor C., Hernandez M., Marcilla I., Luquin M.R. Chronic levodopa administration elicits long-lasting increased number and phenotypic changes in striatal dopaminergic cells in MPTP-monkeys. PLoS One 2012, 7:e50842.
11. Di Monte D.A., McCormack A., Petzinger G., Janson A.M., Quik M., Langston W.J. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov. Disord. 2000, 15:459-466.
12. Doudet D.J., Rosa-Neto P., Munk O.L., Ruth T.J., Jivan S., Cumming P. Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study. Neuroimage 2006, 30:26-35.
13. Espadas I., Darmopil S., Vergaño-Vera E., Ortiz O., Oliva I., Vicario-Abejón C., Martín E.D., Moratalla R. l-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function. Neurobiol. Dis. 2012, 48:271-281.
14. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., Marek K. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 2004, 351:2498-2508. Parkinson Study Group.
15. Fernagut P.O., Li Q., Dovero S., Chan P., Wu T., Ravenscroft P., Hill M., Chen Z., Bezard E. Dopamine transporter binding is unaffected by l-DOPA administration in normal and MPTP-treated monkeys. PLoS One 2010, 5:e14053.
16. Guigoni C., Dovero S., Aubert I., Li Q., Bioulac B.H., Bloch B., Gurevich E.V., Gross C.E., Bezard E. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostriatal lesioning. Eur. J. Neurosci. 2005, 22:283-287.
17. Hadjiconstantinou M., Neff N.H. Enhancing aromatic l-amino acid decarboxylase activity: implications for l-DOPA treatment in Parkinson's disease. CNS Neurosci. Ther. 2008, 14:340-351.
18. Hadjiconstantinou M., Wemlinger T.A., Sylvia C.P., Hubble J.P., Neff N.H. Aromatic l-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors. J. Neurochem. 1993, 60:2175-2180.
19. Hilker R., Schweitzer K., Coburger S., Ghaemi M., Weisenbach S., Jacobs A.H., Rudolf J., Herholz K., Heiss W.D. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch. Neurol. 2005, 62:378-382.
20. Jeon M.Y., Lee W.Y., Kang H.Y., Chung E.J. The effects of l-3,4 dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models. Neurol. Res. 2007, 29:289-295.
21. King J.M., Muthian G., Mackey V., Smith M., Charlton C.L. Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic l-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease. Life Sci. 2011, 89:638-643.
22. Kumakura Y., Cumming P. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neuroscientist 2009, 15:635-650.
23. Lopez A., Munoz A., Guerra M.J., Labandeira-Garcia J.L. Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum. Neuroscience 2001, 103:639-651.
24. Luquin M.R., Montoro R.J., Guillén J., Saldise L., Insausti R., Del Río J., López-Barneo J. Recovery of chronic parkinsonian monkeys by autotransplants of carotid body cell aggregates into putamen. Neuron 1999, 22:743-750.
25. Maetzler W., Liepelt I., Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol. 2009, 8:1158-1171.
26. Morrish P.K., Sawle G.V., Brooks D.J. An [18F]DOPA-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996, 119:585-591.
27. Murer M.G., Dziewczapolski G., Menalled L.B., Garcia M.C., Agid Y., Gershanik O., Raisman-Vozari R. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. 1998, 43:561-575.
28. Nagai Y., Obayashi S., Ando K., Inaji M., Maeda J., Okauchi T., Ito H., Suhara T. Progressive changes of pre- and post-synaptic dopaminergic biomarkers in conscious MPTP-treated cynomolgus monkeys measured by positron emission tomography. Synapse 2007, 61:809-819.
29. Nagatsu T., Sawada M. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J. Neural Transm. Suppl. 2007, 72:113-120.
30. Nandhagopal R., Kuramoto L., Schulzer M., Mak E., Cragg J., Lee C.S., McKenzie J., McCormick S., Samii A., Troiano A., Ruth T.J., Sossi V., de la Fuente-Fernandez R., Calne D.B., Stoessl A.J. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009, 132:2970-2979.
31. Nurmi E., Ruottinen H.M., Bergman J., Haaparanta M., Solin O., Sonninen P., Rinne J.O. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-l-DOPA PET study. Mov. Disord. 2001, 16:608-615.
32. Ordoñez C., Moreno-Murciano P., Hernandez M., Di Caudo C., Carril-Mundiñano I., Vazquez N., Garcia-Verdugo J.M., Sanchez-Pernaute R., Luquin M.R. Sox-2 positive neural progenitors in the primate striatum undergo dynamic changes after dopamine denervation. PLoS One 2013, 8:e66377.
33. Parkinson Study Group Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002, 287:1653-1661.
34. Parkkinen L., O'Sullivan S.S., Kuoppamäki M., Collins C., Kallis C., Holton J.L., Williams D.R., Revesz T., Lees A.J. Does levodopa accelerate the pathologic process in Parkinson disease brain?. Neurology 2011, 77:1420-1426.
35. Pate B.D., Kawamata T., Yamada T., McGeer E.G., Hewitt K.A., Snow B.J., Ruth T.J., Calne D.B. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann. Neurol. 1993, 34:331-338.
36. Rylander D., Parent M., O'Sullivan S.S., Dovero S., Lees A.J., Bezard E., Descarries L., Cenci M.A. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann. Neurol. 2010, 68:619-628.
37. San Sebastian W., Guillen J., Manrique M., Belzunegui S., Ciordia E., Izal-Azcarate A., Garrido-Gil P., Vázquez-Claverie M., Luquin M.R. Modification of the number and phenotype of striatal dopaminergic cells by carotid body graft. Brain 2007, 130:1306-1316.
38. Schneider J.S. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol. Biochem. Behav. 1989, 34:193-196.
39. Shin J.Y., Park H.J., Ahn Y.H., Lee P.H. Neuroprotective effect of l-DOPA on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study. J. Neurochem. 2009, 111:1042-1050.
40. Snow B.J., Tooyama I., McGeer E.G., Yamada T., Calne D.B., Takahashi H., Kimura H. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann. Neurol. 1993, 34:324-330.
41. Stephenson D.T., Childs M.A., Li Q., Carvajal-Gonzalez S., Opsahl A., Tengowski M., Meglasson M.D., Merchant K., Emborg M.E. Differential loss of presynaptic dopaminergic markers in parkinsonian monkeys. Cell Transplant. 2007, 16:229-244.
42. Surti S., Karp J.S., Perkins A.E., Cardi C.A., Daube-Witherspoon M.E., Kuhn A., Muehllehner G. Imaging performance of A-PET: a small animal PET camera. IEEE Trans. Med. Imaging 2005, 24:844-852.
43. Tillerson J.L., Caudle W.M., Reveron M.E., Miller G.W. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp. Neurol. 2002, 178:80-90.
44. Torstenson R., Hartvig P., Langstrom B., Westerberg G., Tedroff J. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Ann. Neurol. 1997, 41:334-340.
45. Vázquez-Claverie M., Garrido-Gil P., San Sebastián W., Izal-Azcárate A., Belzunegui S., Marcilla I., López B., Luquin M.R. Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys. J. Neuropathol. Exp. Neurol. 2009, 68:977-984.
46. Vingerhoets F.J., Snow B.J., Lee C.S., Schulzer M., Mak E., Calne D.B. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann. Neurol. 1994, 36:759-764.
47. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., Lang A.E., Rascol O., Ribeiro M.J., Remy P., Poewe W.H., Hauser R.A., Brooks D.J. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. 2003, 54:93-101. REAL-PET Study Group.
48. Whone A.L., Bailey D.L., Remy P., Pavese N., Brooks D.J. A technique for standardized central analysis of 6-(18)F-fluoro-l-DOPA PET data from a multicenter study. J. Nucl. Med. 2004, 45:1135-1145.
49. Wilson J.M., Levey A.I., Rajput A., Ang L., Guttman M., Shannak K., Niznik H.B., Hornykiewicz O., Pifl C., Kish S.J. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996, 47:718-726.